KraneShares MSCI All China Health Care Index ETF (KURE) provides investors with targeted exposure to the healthcare sector in China. The ETF aims to track the performance of the MSCI All China Health Care Index. This index includes a diverse range of Chinese healthcare companies listed on various global exchanges. It offers broad market representation across different share classes, capturing growth within China's evolving healthcare landscape.
The underlying index comprises numerous companies within the Chinese healthcare industry. It features pharmaceutical companies that actively develop, manufacture, and distribute a wide array of drugs. These offerings include both traditional Chinese medicines and modern pharmaceuticals, based on contemporary scientific research. The index also covers biotechnology firms focusing on the research and development of innovative therapies, advanced vaccines, and sophisticated medical solutions.
Another significant component of the index involves companies specializing in medical equipment and devices. These firms produce a comprehensive range of products essential for modern healthcare delivery. Their offerings include advanced diagnostic imaging systems, precision surgical instruments, and reliable patient monitoring devices. They also manufacture in-vitro diagnostics used for laboratory testing, serving hospitals, clinics, and other healthcare facilities throughout China.
Furthermore, the index includes a variety of healthcare service providers. These operators manage hospitals, specialized clinics, and various treatment centers, offering direct patient care across different medical disciplines. It also covers companies engaged in life sciences tools, advanced diagnostics, and contract research services. These specialized services support the entire drug discovery and development process for pharmaceutical and biotech clients.
The ETF serves both institutional and individual investors seeking focused exposure to the Chinese healthcare industry. It is distributed through established financial intermediaries and accessible via online brokerage platforms, reaching a broad investor base. The fund generates revenue primarily through management fees, offering a recurring service model via channel partners to a global investor base.
KraneShares MSCI All China Health Care Index ETF (KURE) provides investors with targeted exposure to the healthcare sector in China. The ETF aims to track the performance of the MSCI All China Health Care Index. This index includes a diverse range of Chinese healthcare companies listed on various global exchanges. It offers broad market representation across different share classes, capturing growth within China's evolving healthcare landscape.
The underlying index comprises numerous companies within the Chinese healthcare industry. It features pharmaceutical companies that actively develop, manufacture, and distribute a wide array of drugs. These offerings include both traditional Chinese medicines and modern pharmaceuticals, based on contemporary scientific research. The index also covers biotechnology firms focusing on the research and development of innovative therapies, advanced vaccines, and sophisticated medical solutions.
Another significant component of the index involves companies specializing in medical equipment and devices. These firms produce a comprehensive range of products essential for modern healthcare delivery. Their offerings include advanced diagnostic imaging systems, precision surgical instruments, and reliable patient monitoring devices. They also manufacture in-vitro diagnostics used for laboratory testing, serving hospitals, clinics, and other healthcare facilities throughout China.
Furthermore, the index includes a variety of healthcare service providers. These operators manage hospitals, specialized clinics, and various treatment centers, offering direct patient care across different medical disciplines. It also covers companies engaged in life sciences tools, advanced diagnostics, and contract research services. These specialized services support the entire drug discovery and development process for pharmaceutical and biotech clients.
The ETF serves both institutional and individual investors seeking focused exposure to the Chinese healthcare industry. It is distributed through established financial intermediaries and accessible via online brokerage platforms, reaching a broad investor base. The fund generates revenue primarily through management fees, offering a recurring service model via channel partners to a global investor base.
